The published evidence for the clinical validity of the calprotectin ELISA and Quantum Blue® rapid test is ever increasing and described for the diagnosis of IBD vs IBS, as well as for the monitoring of IBD patients during the course of their disease. Please find the printversion of the study summaries here. 1) DIAGNOSIS OF
- info@buhlmannlabs.ch
- +41 61 487 12 12
Blog Archives
Basel, April 2nd, 2015 – BÜHLMANN is pleased to announce the launch of IBDoc®, the first in-vitro diagnostic test to measure the fecal inflammation marker calprotectin at home. IBDoc® just received a CE mark for patient self testing and is a revolutionary new test for gut inflammation aimed at people with Inflammatory Bowel Disease, Crohn’s and Ulcerative Colitis.
BÜHLMANN launched www.ibdoc.net at this year’s UEGW in Vienna. This new website serves as a platform to inform a broad audience about the BÜHLMANN Calprotectin Home Test called IBDoc®. It will also be the first point of contact for IBDoc® users to receive support in the form of Frequently Asked Questions, Instruction for Use documents
Interview with the leader of this evaluation study, Dr. Angelika Ströhle about her positive experiences with this new rapid MDx testing system to detect toxigenic Clostridium difficile bacteria directly from stool samples in 80 minutes with less than 10 minutes Hands-On time. Click here.
Social Links